Research Alliance Corp III
corporate_fare Company Profile
Research Alliance Corp III (NASDAQ:RACC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for RACC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-25, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for RACC spans S-4/A, 425, S-4, 10-Q.
Recent high-impact activity:
- S-4/A Filing Advances Oak Hill Bio Merger as Scalar Flags $9M Net Cash Correction
- Oak Hill Bio Investor Deck Reveals Rugonersen Phase 3 Trial Design and New Efficacy Data
- Rival Angelman Drug Fails Phase 3; Oak Hill Bio's Rugonersen Seen as More Potent
- RACC Files S-4 for Oak Hill Bio Merger: $55M PIPE, $75M Backstop, 42.4% Target Ownership
- RACC Flags Material Weakness and Going Concern Doubt in Q2 10-Q
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 5,523 shares in RACC as of the September 15, 2026 settlement, a 5.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 18.0% of RACC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RACC, detected from its recent SEC filings · based on capital-structure filings through 2026-05-20.
Initial Public Offering Priced · Sponsor Private Placement
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →